大肠癌BRCA-1、ERCC1mRNA表达水平对铂类化疗预后的影响分析  

Analysis of the effect of BRCA-1 and ERCC1 mRNA expression levels in colorectal cancer on the prognosis of platinum-based chemotherapy

作　　者：王先国[1] WANG Xian-guo(Tai’an Cancer Center,Tai’an 271000,China)

机构地区：[1]山东省泰安市肿瘤防治院,271000

出　　处：《中国实用医药》2022年第7期10-13,共4页China Practical Medicine

摘　　要：目的探讨大肠癌乳腺癌易感蛋白1(BRCA-1)、核苷酸切除修复交叉互补基因1信使核糖核酸(ERCC1mRNA)的表达水平对铂类化疗预后的影响。方法58例大肠癌患者,均采用FOLFOX化疗方案治疗。对患者手术标本进行BRCA-1、ERCC1mRNA表达水平检测。分析大肠癌组织中BRCA-1、ERCC1mRNA表达情况及其与临床病理特征、预后的关系,大肠癌组织中BRCA-1、ERCC1mRNA表达的相关性。结果有淋巴结转移患者的BRCA-1阳性表达率46.4%明显低于无淋巴结转移患者的80.0%,差异具有统计学意义(P<0.05)。临床分期越高,ERCC1mRNA阳性表达率越高,不同临床分期比较差异具有统计学意义(P<0.05);有淋巴结转移患者的ERCC1mRNA阳性表达率60.7%明显高于无淋巴结转移患者的26.7%,差异具有统计学意义(P<0.05)。Kaplan-Meier生存分析显示:BRCA-1阳性表达患者的总生存时间为(52.0±4.0)个月,明显长于BRCA-1阴性表达患者的(40.9±3.0)个月,差异具有统计学意义(P<0.05);BRCA-1阳性表达患者的中位生存时间为48.4个月,长于BRCA-1阴性表达患者的44.6个月。ERCC1mRNA阴性表达患者的总生存时间为(48.6±2.0)个月,明显长于ERCC1mRNA阳性表达患者的(43.8±4.7)个月,差异具有统计学意义(P<0.05);ERCC1mRNA阴性表达患者的中位生存时间为45.3个月,明显长于ERCC1mRNA阳性表达患者的41.7个月。Spearman相关分析显示,大肠癌组织中BRCA-1、ERCC1mRNA表达呈负相关性(r=-0.628,P<0.05)。结论BRCA-1阳性、ERCC1mRNA阴性表达的大肠癌患者,在接受铂类药物化疗后中位生存期均较BRCA-1阴性表达、ERCC1mRNA阳性表达患者长。Objective To discuss the effect of breast cancer susceptibility gene 1(BRCA-1)and excision repair cross complementing gene 1 messenger ribonucleic acid(ERCC1 mRNA)expression levels in colorectal cancer on the prognosis of platinum-based chemotherapy.Methods 58 patients with colorectal cancer were treated with FOLFOX chemotherapy.The expression levels of BRCA-1 and ERCC1 mRNA were detected in the surgical specimens of the patients.The expression of BRCA-1 and ERCC1 mRNA in colorectal cancer tissues and their correlation with clinicopathological characteristics and prognosis were analyzed.The correlation of BRCA-1 and ERCC1 mRNA expression in colorectal cancer tissues was analyzed.Results The positive expression rate of BRCA-1 in patients with lymph node metastasis was 46.4%,which was significantly lower than 80.0% in patients without lymph node metastasis,and the difference was statistically significant(P<0.05).The higher the clinical stage,the higher the positive expression rate of ERCC1 mRNA,and the difference in different clinical stages was statistically significant(P<0.05).The positive expression rate of ERCC1 mRNA in patients with lymph node metastasis was 60.7%,which was significantly higher than 26.7%in patients without lymph node metastasis,and the difference was statistically significant(P<0.05).Kaplan-Meier survival analysis showed that the overall survival time of patients with positive expression of BRCA-1 was(52.0±4.0)months,which was significantly longer than(40.9±3.0)months of patients with negative expression of BRCA-1,and the difference was statistically significant(P<0.05).The median survival time of patients with positive expression of BRCA-1 was 48.4 months,which was longer than 44.6 months of patients with negative expression of BRCA-1.The overall survival time of patients with negative expression of ERCC1 mRNA was(48.6±2.0)months,which was significantly longer than(43.8±4.7)months of patients with positive expression of ERCC1 mRNA,and the difference was statistically significant(P<0.05).

关 键 词：大肠癌 乳腺癌易感蛋白1 核苷酸切除修复交叉互补基因1 铂类化疗 预后 

分 类 号：R735.34[医药卫生—肿瘤]